Andrew J. Schwab - 31 Jan 2024 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SKYE	Common Stock	Award	$12,026,031	+5,206,074	+190%	$2.31	7,943,520	31 Jan 2024	By 5AM Ventures VII, L.P.	F1
holding	SKYE	Common Stock						1,718,189	31 Jan 2024	By 5AM Ventures II, L.P.	F2
holding	SKYE	Common Stock						67,796	31 Jan 2024	By 5AM Co-Investors II, L.P.	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F2	The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F3	The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.